chr1-45332886-TCCTATTTCCCCTA-T
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_001048174.2(MUTYH):c.420+19_420+31delTAGGGGAAATAGG variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00000342 in 1,461,820 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: not found (cov: 32)
Exomes 𝑓: 0.0000034 ( 0 hom. )
Consequence
MUTYH
NM_001048174.2 intron
NM_001048174.2 intron
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 1.76
Genes affected
MUTYH (HGNC:7527): (mutY DNA glycosylase) This gene encodes a DNA glycosylase involved in oxidative DNA damage repair. The enzyme excises adenine bases from the DNA backbone at sites where adenine is inappropriately paired with guanine, cytosine, or 8-oxo-7,8-dihydroguanine, a major oxidatively damaged DNA lesion. The protein is localized to the nucleus and mitochondria. This gene product is thought to play a role in signaling apoptosis by the introduction of single-strand breaks following oxidative damage. Mutations in this gene result in heritable predisposition to colorectal cancer, termed MUTYH-associated polyposis (MAP). Multiple transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2017]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 1-45332886-TCCTATTTCCCCTA-T is Pathogenic according to our data. Variant chr1-45332886-TCCTATTTCCCCTA-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 406825.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-45332886-TCCTATTTCCCCTA-T is described in Lovd as [Pathogenic]. Variant chr1-45332886-TCCTATTTCCCCTA-T is described in Lovd as [Likely_pathogenic]. Variant chr1-45332886-TCCTATTTCCCCTA-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| MUTYH | ENST00000456914.7 | c.420+19_420+31delTAGGGGAAATAGG | intron_variant | Intron 6 of 15 | 1 | NM_001048174.2 | ENSP00000407590.2 | |||
| ENSG00000288208 | ENST00000671898.1 | n.1008+19_1008+31delTAGGGGAAATAGG | intron_variant | Intron 10 of 20 | ENSP00000499896.1 |
Frequencies
GnomAD3 genomes
GnomAD3 genomes
Cov.:
32
GnomAD3 exomes AF: 0.00000797 AC: 2AN: 251048Hom.: 0 AF XY: 0.00 AC XY: 0AN XY: 135684
GnomAD3 exomes
AF:
AC:
2
AN:
251048
Hom.:
AF XY:
AC XY:
0
AN XY:
135684
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00000342 AC: 5AN: 1461820Hom.: 0 AF XY: 0.00000413 AC XY: 3AN XY: 727210
GnomAD4 exome
AF:
AC:
5
AN:
1461820
Hom.:
AF XY:
AC XY:
3
AN XY:
727210
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome
GnomAD4 genome
Cov.:
32
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:11
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Pathogenic:4
| Pathogenic, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jan 25, 2022 | The MUTYH c.504+19_504+31del variant (rs781222233) is reported in the literature in the compound heterozygous or homozygous state in several individuals and families affected with MUTYH-associated polyposis (Di Gregorio 2006, Fostira 2010, Jones 2009, Morak 2010, Papp 2016, Vogt 2009). This variant is also reported in ClinVar (Variation ID: 406825), and is only observed on two alleles in the Genome Aggregation Database, indicating it is not a common polymorphism. This is an intronic variant that deleted 13 nucleotides of intron 6, and in vitro functional analyses demonstrate skipping of exon 6, leading to an in-frame deletion that removes part of the critical glycosylase catalytic domain (Fostira 2010). Based on available information, this variant is considered to be pathogenic. References: Di Gregorio C et al. Immunohistochemical expression of MYH protein can be used to identify patients with MYH-associated polyposis. Gastroenterology. 2006 Aug;131(2):439-44. PMID: 16890597. Fostira F et al. An in-frame exon-skipping MUTYH mutation is associated with early-onset colorectal cancer. Dis Colon Rectum. 2010 Aug;53(8):1197-201. PMID: 20628285. Jones N et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology. 2009 Aug;137(2):489-94, 494.e1; quiz 725-6. PMID: 19394335. Morak M et al. MUTYH-associated polyposis - variability of the clinical phenotype in patients with biallelic and monoallelic MUTYH mutations and report on novel mutations. Clin Genet. 2010 Oct;78(4):353-63. PMID: 20618354. Papp J et al. Contribution of APC and MUTYH mutations to familial adenomatous polyposis susceptibility in Hungary. Fam Cancer. 2016 Jan;15(1):85-97. PMID: 26446593. Vogt S et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology. 2009 Dec;137(6):1976-85.e1-10. PMID: 19732775. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Clinical Genetics Laboratory, Skane University Hospital Lund | Nov 28, 2022 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Oct 01, 2023 | MUTYH: PM3:Strong, PM2, PS3:Supporting, PS4:Supporting - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 08, 2018 | - - |
Familial adenomatous polyposis 2 Pathogenic:4
| Pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Mar 17, 2023 | - - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | All of Us Research Program, National Institutes of Health | Jun 26, 2023 | This variant causes a 13 base pair deletion in intron 6 of the MUTYH gene. An RNA study found this variant resulted in the in-frame skipping of exon 6 (PMID: 20628285). This variant has been reported in compound heterozygous and homozygous carriers with polyposis and/or colorectal cancer (PMID: 16890597, 19732775, 20618354, 20628285, 26446593, 27829682). In particular, this variant was observed in the compound heterozygous state with a pathogenic variant, c.1437_1439del, in an individual affected with polyps and colorectal cancer (PMID: 20628285). The proband's mother, who was heterozygous for this variant, as well as the proband's sister, who was heterozygous for c.1437_1439del variant, were unaffected with polyps and colorectal cancer. This variant was also observed in homozygosity in three siblings in a different family (PMID: 20628285). Their heterozygous mother, father, and one sibling were unaffected with polyps and colorectal cancer (PMID: 20628285). This variant has been identified in 2/251048 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MUTYH function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic. - |
| Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Apr 23, 2018 | - - |
| Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Nov 19, 2024 | This sequence change falls in intron 6 of the MUTYH gene. It does not directly change the encoded amino acid sequence of the MUTYH protein. RNA analysis indicates that this variant induces altered splicing and likely results in a shortened protein product. This variant is present in population databases (rs781222233, gnomAD 0.002%). This variant has been observed in individual(s) with MUTYH-associated polyposis (PMID: 16890597, 19732775, 20628285, 21520333). In at least one individual the data is consistent with being in trans (on the opposite chromosome) from a pathogenic variant. It has also been observed to segregate with disease in related individuals. This variant is also known as IVS6+19-31del13. ClinVar contains an entry for this variant (Variation ID: 406825). Studies have shown that this variant results in skipping of exon 6, but is expected to preserve the integrity of the reading-frame (PMID: 20628285; internal data). For these reasons, this variant has been classified as Pathogenic. - |
Hereditary cancer-predisposing syndrome Pathogenic:2
| Likely pathogenic, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Jun 14, 2023 | This variant causes a 13 base pair deletion in intron 6 of the MUTYH gene. An RNA study found this variant resulted in the in-frame skipping of exon 6 (PMID: 20628285). This variant has been reported in compound heterozygous and homozygous carriers with polyposis and/or colorectal cancer (PMID: 16890597, 19732775, 20618354, 20628285, 26446593, 27829682). In particular, this variant was observed in the compound heterozygous state with a pathogenic variant, c.1437_1439del, in an individual affected with polyps and colorectal cancer (PMID: 20628285). The proband's mother, who was heterozygous for this variant, as well as the proband's sister, who was heterozygous for c.1437_1439del variant, were unaffected with polyps and colorectal cancer. This variant was also observed in homozygosity in three siblings in a different family (PMID: 20628285). Their heterozygous mother, father, and one sibling were unaffected with polyps and colorectal cancer (PMID: 20628285). This variant has been identified in 2/251048 chromosomes in the general population by the Genome Aggregation Database (gnomAD). Loss of MUTYH function is a known mechanism of disease (clinicalgenome.org). Based on the available evidence, this variant is classified as Likely Pathogenic. - |
| Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Feb 19, 2024 | The c.504+19_504+31del13 intronic pathogenic mutation is located 19 nucleotides after coding exon 6 in the MUTYH gene. This variant results from a deletion of 13 nucleotides at positions c.504+19 to c.504+31. This variant has been reported in the homozygous state as well as in conjunction with MUTYH pathogenic mutations in individuals with adenomatous polyposis and co-segregated with disease in three affected siblings of a family (Di Gregorio C et al. Gastroenterology, 2006 Aug;131:439-44; Jones N et al. Gastroenterology, 2009 Aug;137:489-94, 494.e1; quiz 725-6; Vogt S et al. Gastroenterology, 2009 Dec;137:1976-85.e1-10; Fostira F et al. Dis. Colon Rectum, 2010 Aug;53:1197-201; Papp J et al. Fam. Cancer, 2016 Jan;15:85-97). Analysis by RT-PCR using RNA from a patient homozygous for this variant and a compound heterozygous patient was reported to result in complete in-frame skipping of MUTYH coding exon 6 (Fostira F et al. Dis. Colon Rectum, 2010 Aug;53:1197-201). RNA studies have demonstrated that this alteration results in abnormal splicing in the set of samples tested (Ambry internal data). Based on an internal structural analysis, deletion of MUTYH coding exon 6 would be structurally deleterious (Ambry internal data). These nucleotide positions are not well conserved in available vertebrate species. In silico splice site analysis for this alteration is inconclusive. This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
Colonic neoplasm Pathogenic:1
| Likely pathogenic, no assertion criteria provided | clinical testing | Medical Genetics Laboratory, Umraniye Training and Research Hospital, University of Health Sciences | Aug 21, 2021 | Medullary Carcinoma EST= - PRO = - HER2 = - KI = - - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at